voruciclib + vemurafenib

A **combination therapy** of voruciclib (P1446A-05), a potent oral multi-cyclin-dependent kinase (CDK) inhibitor, and vemurafenib, a selective BRAF inhibitor. **Voruciclib** targets CDK4, CDK6, CDK1, and CDK9, inducing cell cycle arrest and apoptosis by blocking cell cycle progression and transcriptional regulation. **Vemurafenib** inhibits mutated BRAF (most commonly V600E), a key driver of uncontrolled proliferation in BRAF-mutant melanoma. The combination is explored to overcome rapid resistance commonly observed with BRAF inhibitors alone. Early phase clinical data show the combination is generally well tolerated with preliminary efficacy, especially in BRAF inhibitor–naïve melanoma patients[1][3].